Amgen climbs on osteoporosis drug approval
BOSTON (MarketWatch) — Shares of Amgen Inc. rose in early trading Wednesday, the morning after the biotech group announced that it has won U.S. regulatory approval for its drug Prolia for the treatment of osteoporosis in postmenopausal women. Amgen shares were up 6% at $53.84. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for …

Read more on Market Watch